CellAegis Devices (Toronto, Canada) has patented and developed the non-invasive autoRIC Device, which delivers Remote Ischemic Conditioning (RIC) therapy to patients with acute and chronic cardiovascular conditions. RIC therapy is based on the principle of adaptive physiology, where short, deliberate occlusion of blood flow to the arm activates the cellular survival network against ischemia. This medical procedure protects the heart as well as other organs from ischemia and reperfusion injury.

The autoRIC Device has the CE Mark and Health Canada approval for adjunct treatment during heart attacks, cardiothoracic or surgical procedures, and is being developed for chronic conditions such as heart failure and stroke. The autoRIC Device was developed from the clinical work of Dr. Andrew Redington and colleagues, who are part of the Fondation Leducq TransAtlantic network.

http://www.cellaegisdevices.com/